Neuroblastoma pp 257-265 | Cite as


  • Darrell J. Yamashiro
  • Susan L. Cohn
Part of the Pediatric Oncology book series (PEDIATRICO)


Vascular Endothelial Growth Factor Schwann Cell Vascular Endothelial Growth Factor Receptor Vascular Endothelial Growth Factor Family Neuroblastoma Tumor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, Okada A (1998) Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 33:1272–1278CrossRefPubMedGoogle Scholar
  2. Bergers G, Benjamin LE (2003) Angiogenesis: tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410CrossRefPubMedGoogle Scholar
  3. Breit S, Ashman K, Wilting J, Rossler J, Hatzi E, Fotsis T, Schweigerer L (2000) The N-myc oncogene in human neuroblastoma cells: down-regulation of an angiogenesis inhibitor identified as activin A. Cancer Res 60:4596–4601PubMedGoogle Scholar
  4. Brekken RA, Sage EH (2001) SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 19:816–827CrossRefPubMedGoogle Scholar
  5. Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347–356PubMedGoogle Scholar
  6. Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart-Bosch A (2000) Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 18:27–34PubMedGoogle Scholar
  7. Castle VP, Ou X, O'Shea S, Dixit VM (1992) Induction of thrombospondin 1 by retinoic acid is important during differentiation of neuroblastoma cells. J Clin Invest 90:1857–1863PubMedGoogle Scholar
  8. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL (2002) SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 62:7357–7363PubMedGoogle Scholar
  9. Clauss M (2000) Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 26:561–569CrossRefPubMedGoogle Scholar
  10. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, De Vries GH, Abramson LP, Bouck N (2001) Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 114:4421–4428PubMedGoogle Scholar
  11. Dameron KM, Volpert OV, Tainsky MA, Bouck N (1994) Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582–1584PubMedGoogle Scholar
  12. Davidoff AM, Leary MA, Ng CY, Spurbeck WW, Frare P, Vanhove M, Nienhuis AW, Vanin EF (2001a) Autocrine expression of both endostatin and green fluorescent protein provides a synergistic antitumor effect in a murine neuroblastoma model. Cancer Gene Ther 8:537–545CrossRefPubMedGoogle Scholar
  13. Davidoff AM, Leary MA, Ng CY, Vanin EF (2001b) Gene therapy-mediated expression by tumor cells of the angiogenesis inhibitor flk-1 results in inhibition of neuroblastoma growth in vivo. J Pediatr Surg 36:30–36CrossRefPubMedGoogle Scholar
  14. Dixelius J, Cross M, Matsumoto T, Sasaki T, Timpl R, Claesson-Welsh L (2002) Endostatin regulates endothelial cell adhesion and cytoskeletal organization. Cancer Res 62:1944–1947PubMedGoogle Scholar
  15. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6:1900–1908PubMedGoogle Scholar
  16. Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, Stins MF, Seeger RC, Durden DL (2000) Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 60:712–721PubMedGoogle Scholar
  17. Fakhari M, Pullirsch D, Abraham D, Paya K, Hofbauer R, Holzfeind P, Hofmann M, Aharinejad S (2002) Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and-2 in human neuroblastoma. Cancer 94:258–263CrossRefPubMedGoogle Scholar
  18. Fakhari M, Pullirsch D, Paya K, Abraham D, Hofbauer R, Aharinejad S (2002) Upregulation of vascular endothelial growth factor receptors is associated with advanced neuroblastoma. J Pediatr Surg 37:582–587CrossRefPubMedGoogle Scholar
  19. Ferrara N (2001) Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280:C1358–C1366PubMedGoogle Scholar
  20. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18CrossRefGoogle Scholar
  21. Folkman J, Merler E, Abernathy C, Williams G (1971) Isolation of a tumor factor responsible or angiogenesis. J Exp Med 133:275–288CrossRefPubMedGoogle Scholar
  22. Fukuzawa M, Sugiura H, Koshinaga T, Ikeda T, Hagiwara N, Sawada T (2002) Expression of vascular endothelial growth factor and its receptor Flk-1 in human neuroblastoma using in situ hybridization. J Pediatr Surg 37:1747–1750CrossRefPubMedGoogle Scholar
  23. Glade-Bender J, Kandel JJ, Yamashiro DJ (2003) VEGF blocking therapy in the treatment of cancer. Exp Opin Biol Ther 3:263–276CrossRefGoogle Scholar
  24. Hasan J, Byers R, Jayson GC (2002) Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86:1566–1577CrossRefPubMedGoogle Scholar
  25. Hatzi E, Breit S, Zoephel A, Ashman K, Tontsch U, Ahorn H, Murphy C, Schweigerer L, Fotsis T (2000) MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. Adv Exp Med Biol 476:239–248PubMedGoogle Scholar
  26. Hatzi E, Murphy C, Zoephel A, Ahorn H, Tontsch U, Bamberger AM, Yamauchi-Takihara K, Schweigerer L, Fotsis T (2002a) N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. Eur J Biochem 269:3732–3741CrossRefPubMedGoogle Scholar
  27. Hatzi E, Murphy C, Zoephel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takihara K, Ziche M, Rofstad EK, Schweigerer L, Fotsis T (2002b) N-myc oncogene overexpression down-regulates IL-6; evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. Oncogene 21:3552–3561CrossRefPubMedGoogle Scholar
  28. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M (2002) MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300CrossRefPubMedGoogle Scholar
  29. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398CrossRefPubMedGoogle Scholar
  30. Huang D, Rutkowski JL, Brodeur GM, Chou PM, Kwiatkowski JL, Babbo A, Cohn SL (2000) Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res 60:5966–5971PubMedGoogle Scholar
  31. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348:555–557CrossRefPubMedGoogle Scholar
  32. Jouanneau E, Alberti L, Nejjari M, Treilleux I, Vilgrain I, Duc A, Combaret V, Favrot M, Leboulch P, Bachelot T (2001) Lack of antitumor activity of recombinant endostatin in a human neuroblastoma xenograft model. J Neurooncol 51:11–18CrossRefPubMedGoogle Scholar
  33. Katzenstein HM, Rademaker AW, Senger C, Salwen HR, Nguyen NN, Thorner PS, Litsas L, Cohn SL (1999) Effectiveness of the angiogenesis inhibitor TNP-470 in reducing the growth of human neuroblastoma in nude mice inversely correlates with tumor burden. Clin Cancer Res 5:4273–4278PubMedGoogle Scholar
  34. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG (2000) Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 60:5410–5413PubMedGoogle Scholar
  35. Kim E, Moore J, Huang J, Soffer S, Manley CA, O'Toole K, Middlesworth W, Stolar CJ, Kandel JJ, Yamashiro DJ (2001) All angiogenesis is not the same: distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg 36:287–290CrossRefPubMedGoogle Scholar
  36. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ (2002a) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399–11404CrossRefPubMedGoogle Scholar
  37. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG (2002b) Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 277:27872–27879CrossRefPubMedGoogle Scholar
  38. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15–R24PubMedGoogle Scholar
  39. Komuro H, Kaneko S, Kaneko M, Nakanishi Y (2001) Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127:739–743PubMedGoogle Scholar
  40. Kurebayashi J, Kurosumi M, Dickson RB, Sonoo H (1994) Angiogenesis inhibitor O-(Chloroacetyl-carbamoyl) fumagillol (TNP-470) inhibits tumor angiogenesis, growth and spontaneous metastasis of MKL-4 human breast cancer cells in female athymic nude mice. Breast Cancer 1:109–115PubMedGoogle Scholar
  41. Kuroiwa M, Ikeda H, Hongo T, Tsuchida Y, Hirato J, Kaneko Y, Suzuki N, Obana K, Makino SI (2001) Effects of recombinant human endostatin on a human neuroblastoma xenograft. Int J Mol Med 8:391–396PubMedGoogle Scholar
  42. Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J (1991) Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 174:1070–1076CrossRefPubMedGoogle Scholar
  43. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P (2000) Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med Pediatr Oncol 34:386–393CrossRefPubMedGoogle Scholar
  44. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedGoogle Scholar
  45. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194–1201CrossRefPubMedGoogle Scholar
  46. Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L, Mohle R (1999) Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 35:445–449CrossRefPubMedGoogle Scholar
  47. Meitar D, Crawford SE, Rademaker AW, Cohn SL (1996) Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:405–414PubMedGoogle Scholar
  48. Nagabuchi E, VanderKolk WE, Une Y, Ziegler MM (1997) TNP-470 antiangiogenic therapy for advanced murine neuroblastoma. J Pediatr Surg 32:287–293CrossRefPubMedGoogle Scholar
  49. Neufeld G, Cohen T, Shraga N, Lange T, Kessler O, Herzog Y (2002) The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med 12:13–19CrossRefPubMedGoogle Scholar
  50. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285PubMedGoogle Scholar
  51. Overall CM, Lopez-Otin C (2002) Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2:657–672CrossRefPubMedGoogle Scholar
  52. Pijuan-Thompson V, Grammer JR, Stewart J, Silverstein RL, Pearce SF, Tuszynski GP, Murphy-Ullrich JE, Gladson CL (1999) Retinoic acid alters the mechanism of attachment of malignant astrocytoma and neuroblastoma cells to thrombospondin-1. Exp Cell Res 249:86–101CrossRefPubMedGoogle Scholar
  53. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K (2001) Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 98:1024–1029CrossRefPubMedGoogle Scholar
  54. Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC (2002) Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer 98:682–689CrossRefPubMedGoogle Scholar
  55. Ribatti D, Alessandri G, Vacca A, Iurlaro M, Ponzoni M (1998) Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 77:449–454CrossRefPubMedGoogle Scholar
  56. Ribatti D, Surico G, Vacca A, De Leonardis F, Lastilla G, Montaldo PG, Rigillo N, Ponzoni M (2001) Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with progression in human neuroblastoma. Life Sci 68:1161–1168CrossRefPubMedGoogle Scholar
  57. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M (2002) In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 102:351–354CrossRefPubMedGoogle Scholar
  58. Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML (2001) Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA 98: 12485–12490CrossRefPubMedGoogle Scholar
  59. Rossler J, Breit S, Havers W, Schweigerer L (1999) Vascular endothelial growth factor expression in human neuroblastoma: up-regulation by hypoxia. Int J Cancer 81:113–117CrossRefPubMedGoogle Scholar
  60. Rowe DH, Huang J, Li J, Manley C, O'Toole KM, Stolar CJ, Yamashiro DJ, Kandel JJ (2000) Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg 35:977–981CrossRefPubMedGoogle Scholar
  61. Sakakibara M, Koizumi S, Saikawa Y, Wada H, Ichihara T, Sato H, Horita S, Mugishima H, Kaneko Y, Koike K (1999) Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 85:231–239CrossRefPubMedGoogle Scholar
  62. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM (2001) The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin Cancer Res 7:977–984PubMedGoogle Scholar
  63. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–745CrossRefPubMedGoogle Scholar
  64. Sugiura Y, Shimada H, Seeger RC, Laug WE, DeClerck YA (1998) Matrix metalloproteinases-2 and-9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res 58:2209–2216PubMedGoogle Scholar
  65. Yamaoka M, Yamamoto T, Ikeyama S, Sudo K, Fujita T (1993a) Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53: 5233–5236PubMedGoogle Scholar
  66. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T (1993b) Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 53:4262–4267PubMedGoogle Scholar
  67. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295:1526–1528CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Darrell J. Yamashiro
  • Susan L. Cohn

There are no affiliations available

Personalised recommendations